Ask HopeStage to review this study with me
Study ID: NCT06605599. We help you review the study, but cannot decide medical eligibility.
CompletedNCT06605599
Safety study of Efficacy, Safety, and Tolerability of ABBV-932 in depression
This study is completed in the United States and in Japan. It is testing Efficacy, Safety, and Tolerability of ABBV-932 for depression.
BipolarityDrugFrom 18 Years to 65 Years
Key information made simple
What is this study testing?
This study is testing whether Oral ABBV-932 may be useful for adults experiencing bipolarity.
What would participation involve?
Participants may receive Oral ABBV-932, complete questionnaires or follow-up assessments, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Japan and in the United States.
Who is it mainly for?
This study appears to be mainly for adults with bipolarity.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record lists this AbbVie study as completed, with sites in the United States, Japan, and Puerto Rico. Participation involved oral capsules of ABBV-932 or placebo, weekly clinic visits during the 6-week treatment period, medical assessments, blood tests, side-effect checks, questionnaires, and a 4-week safety follow-up. The main fit was adults aged 18 to 65 with bipolarity type I or II, without psychotic features, who were in a current depressive episode and met the study's symptom-score requirements. Key exclusions included a positive urine drug screen, recent investigational drug use, current enrollment in another clinical study, recent use of psychoactive medication, and prior recent exposure to ABBV-932.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: October 15, 2024
- Recruitment status
- Completed
- Estimated enrollment
- 161
- Sponsor
- AbbVie
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Japan
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06605599
- Official title
- Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 in Subjects With Depressive Episodes Associated With Bipolar I or II Disorder
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT06605599. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular follow-up, often through questionnaires or interviews.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with bipolarity; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by AbbVie, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join. The registry lists an estimated enrollment of 161 participants.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT00223496
12- Week Open Label Treatment of Refractory Depression in bipolarity
This study is completed. It focuses on bipolarity and currently lists study information in the United States.
CompletedNCT02363738
12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression
This study is completed. It focuses on bipolarity and currently lists study information in Canada and the United States.
CompletedNCT03902613
18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolarity
This study is completed. It focuses on bipolarity and currently lists study information in the United States.